Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adults greater than 18 years of age with documented HIV infection
Highly active antiretroviral therapy (HAART) regimens as defined by the Department of Health and Human Services guidelines; stable regimens for 12 weeks.
CD4 greater than 200 at time of study enrollment
Stable monitoring labs (hematology survey with differential, ALT, creatinine)
Absolute neutrophil count within normal limits
AIDS defining illness within the last 6 months
Acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections
Women who are pregnant or nursing
Hypersensitivity to etanercept
Previous use of etanercept
Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common skin cancers (non melanoma)
History of active or latent tuberculosis
History of demyelinating nerve disease
History of seizure disorder
Subject has any of the following laboratory values within 30 days of baseline:
hemoglobin concentration < 10.0 g/dl for men and < 9.0 g/dl for women
platelet count < 75,000/mm3
AST or ALT > 5x upper limit of normal (ULN)
serum creatinine > 2.5x ULN
serum pancreatic amylase > 1.5 ULN
Subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon
Subjects who chronically use any over-the-counter (OTC) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.